Fierce Pharma

ESMO: AstraZeneca faces challenge with FDA as Imfinzi, Lynparza miss survival goal in ovarian cancer

More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival ...
Fierce Pharma

ESMO: AZ, Daiichi’s Datroway outshines Gilead’s Trodelvy in first global TROP2 showdown

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...
Fierce Pharma

ESMO: Merck spotlights details of Keytruda's landmark win in ovarian cancer

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda proves to ...
Fierce Pharma

ESMO: AZ, Daiichi unleash Enhertu's 2-fisted power, aiming to reshape early breast cancer landscape

AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials. | AstraZeneca and Daiichi ...
Fierce Pharma

ESMO: Keytruda, Padcev reduce risk of death by 50% in another massive showing in bladder cancer

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...